Abstract 4908: Exemestane worsens everolimus-associated stomatitis in cancer patients
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4908
Abstract: Everolimus is an antitumor drug usually indicated for the treatment of breast, kidney and neuroendocrine malignancies that inhibits the activation of the mammalian Target of Rapamycin (mTOR). Despite the efficacy and success of the treatment,… read more here.
Keywords: exemestane; everolimus associated; cancer; cancer patients ... See more keywords